Earnings Releases·Nov 5, 2026, 4:08 PM ET

Janux Therapeutics — Third Quarter 2026 Earnings Summary

Collaboration revenue declined 7% year-over-year to $9.3 million, while R&D and G&A expenses decreased to $30.6 million and $10.0 million respectively, resulting in a net loss of $21.6 million versus $24.3 million in the prior year period.
Cash and investments decreased to $945.7 million as of September 30, 2026, from $966.6 million at year-end 2025, while total liabilities rose to $72.0 million primarily due to $27.2 million in recognized current deferred revenue.
Clinical advancement includes JANX007 advancing through Phase 1b with ongoing dose optimization and combination studies, JANX014 continuing Phase 1 enrollment, and JANX013 dosing its first patient in a Phase 1 combination study.
Upcoming milestones include the presentation of initial JANX011 Phase 1 healthy volunteer data on November 9, 2026, and expected JANX007 Phase 1b data at a medical congress in the first half of 2027.